A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety,
tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers
of XL092 administered alone, in combination with atezolizumab, and in combination with
avelumab to subjects with advanced solid tumors.